New hope for deadly cancer: First-in-Human trial tests engineered immune cells
NCT ID NCT07153289
Summary
This trial is testing a new type of personalized immune cell therapy (CAR-T) for advanced pancreatic cancer that has stopped responding to standard treatments. Doctors will collect a patient's own immune cells, genetically modify them to target a protein called CD318 found on pancreatic cancer cells, and infuse them back into the patient. The main goals are to see if this approach is safe and feasible, and to look for early signs that it can shrink tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.